STOCK TITAN

Twist Bioscience holder plans $282K stock sale

Rule 144 filing for Twist Bioscience common stock discloses planned sales by Emily M. Leproust tied to vesting compensation and related tax obligations.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) received a Rule 144 notice relating to planned sales of its common stock by Emily M. Leproust through Fidelity Brokerage Services LLC. The notice covers an intended sale of up to 2,302 shares of common stock, with an aggregate market value of $282,280.22 as of September 8, 2026.

The shares to be sold arise from restricted stock vesting on September 4, 2026, reported as a compensation-related distribution by the issuer. The filer also discloses multiple prior sales of Twist common stock during the past three months, and notes that the current sale includes shares to cover a tax obligation from settlement of a vested equity award.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 2,302 shares Intended Rule 144 sale of Twist Bioscience common stock
Aggregate market value of planned sale $282,280.22 Value of 2,302 shares as of September 8, 2026
Shares sold on August 10, 2026 113,318 shares Previously sold Twist Bioscience common stock in one transaction
Dollar value of August 10, 2026 sale $14,183,062.19 Proceeds from that single prior sale of common stock
Shares sold on June 25, 2026 18,880 shares Previously reported sale of Twist Bioscience common stock
Dollar value of June 25, 2026 sale $1,793,600.00 Proceeds from that June 25, 2026 transaction
Shares sold on August 25, 2026 41,570 shares Previously reported sale of Twist Bioscience common stock
Dollar value of August 25, 2026 sale $6,317,760.97 Proceeds from that August 25, 2026 transaction
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting financial
"Common | 09/04/2026 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
vested equity award financial
"tax obligation resulting from the settlement of a vested equity award distribution."
compensation financial
"09/04/2026 | Compensation"
attorney-in-fact regulatory
"as attorney-in-fact for Emily M. Leproust"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Rule 144 filing for TWST disclose about upcoming stock sales?

The Rule 144 notice reports an intended sale of up to 2,302 shares of Twist Bioscience common stock by Emily M. Leproust through Fidelity Brokerage Services LLC, with an aggregate market value of $282,280.22 as of September 8, 2026.

Who is selling Twist Bioscience (TWST) shares in this Rule 144 notice?

The notice identifies Emily M. Leproust as the person for whose account Twist Bioscience common stock is to be sold, with Fidelity Brokerage Services LLC acting as the broker and signing through a duly authorized representative as attorney-in-fact.

What is the source of the TWST shares being sold under this Rule 144 filing?

The securities to be sold are Twist Bioscience common shares received from restricted stock vesting on September 4, 2026, categorized as a compensation-related distribution from the issuer.

How much Twist Bioscience (TWST) stock has been sold in the last three months by this filer?

The filing lists several prior sales of Twist Bioscience common stock by Emily M. Leproust over the past three months, including transactions on June 8, June 22, June 25, August 3, August 10, August 12, August 21, and August 25, 2026, each with stated share amounts and dollar values.

Does the Rule 144 sale for TWST include shares to cover taxes?

Yes. The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution, indicating part of the sale is for tax-related purposes.

On which market is the Twist Bioscience (TWST) stock in this filing traded?

The Rule 144 information identifies the common stock as traded on NASDAQ, with the broker listed as Fidelity Brokerage Services LLC and the relevant date for the reported market value as September 8, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading